{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:45:14Z","timestamp":1792129514741,"version":"4.4.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1053\/j.seminhematol.2026.07.003","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:05:20Z","timestamp":1785510320000},"page":"136-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Blood or marrow transplantation and cellular therapies in myeloproliferative neoplasms: A comprehensive review"],"prefix":"10.1053","volume":"63","author":[{"given":"Kanishka Uttam","family":"Chandani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-773X","authenticated-orcid":false,"given":"Tania","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1053\/j.seminhematol.2026.07.003_bib0001","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Editorial: some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.07.003_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-007-0403-6","article-title":"The diagnosis of BCR\/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers","volume":"87","author":"Haferlach","year":"2008","journal-title":"Ann Hematol"},{"issue":"22","key":"10.1053\/j.seminhematol.2026.07.003_bib0003","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.07.003_bib0004","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/asheducation-2003.1.200","article-title":"Chronic myeloproliferative disorders","volume":"2003","author":"Spivak","year":"2003","journal-title":"Hematology"},{"issue":"17","key":"10.1053\/j.seminhematol.2026.07.003_bib0005","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","article-title":"How I treat myelofibrosis","volume":"124","author":"Cervantes","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.07.003_bib0006","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s11899-019-00508-w","article-title":"Key role of inflammation in myeloproliferative neoplasms: instigator of disease initiation, progression and symptoms","volume":"14","author":"Mendez Luque","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1053\/j.seminhematol.2026.07.003_bib0007","doi-asserted-by":"crossref","DOI":"10.1155\/mi\/9967975","article-title":"Chronic inflammation in primary myelofibrosis: in-depth insights into pathogenesis and promising anti-inflammatory therapeutic strategies","volume":"2025","author":"Chen","year":"2025","journal-title":"Mediators Inflamm"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.07.003_bib0008","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases","volume":"105","author":"Mesa","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.07.003_bib0009","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.hoc.2020.12.008","article-title":"Accelerated and blast phase myeloproliferative neoplasms","volume":"35","author":"Jain","year":"2021","journal-title":"Hematol\/Oncol Clin"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.07.003_bib0010","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.07.003_bib0011","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","article-title":"Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study","volume":"4","author":"Harrison","year":"2017","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.07.003_bib0012","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.07.003_bib0013","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.07.003_bib0014","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","article-title":"A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis","volume":"100","author":"Vannucchi","year":"2015","journal-title":"Haematologica"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.07.003_bib0015","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/bloodadvances.2019001084","article-title":"Survival following allogeneic transplant in patients with myelofibrosis","volume":"4","author":"Gowin","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.07.003_bib0016","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/S2352-3026(23)00305-8","article-title":"Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT\/ELN International Working Group","volume":"11","author":"Kroger","year":"2024","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.07.003_bib0017","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.bbmt.2017.05.007","article-title":"Allogeneic stem cell transplantation in myelofibrosis","volume":"23","author":"Jain","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.07.003_bib0018","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.07.003_bib0019","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.07.003_bib0020","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1038\/s41375-018-0078-0","article-title":"U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"17","key":"10.1053\/j.seminhematol.2026.07.003_bib0021","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1200\/JCO.2018.78.9867","article-title":"MIPSS70+ version 2.0: mutation and karyotype-enhanced international prognostic scoring system for primary myelofibrosis","volume":"36","author":"Tefferi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"50","key":"10.1053\/j.seminhematol.2026.07.003_bib0022","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"25","key":"10.1053\/j.seminhematol.2026.07.003_bib0023","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1182\/blood-2009-06-223982","article-title":"AML1\/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms","volume":"114","author":"Ding","year":"2009","journal-title":"Blood"},{"issue":"15","key":"10.1053\/j.seminhematol.2026.07.003_bib0024","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.07.003_bib0025","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","article-title":"JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis","volume":"110","author":"Barosi","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.07.003_bib0026","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41375-018-0018-z","article-title":"Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.07.003_bib0027","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.07.003_bib0028","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.07.003_bib0029","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","article-title":"Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group","volume":"29","author":"Kr\u00f6ger","year":"2015","journal-title":"Leukemia"},{"issue":"15","key":"10.1053\/j.seminhematol.2026.07.003_bib0030","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1182\/bloodadvances.2022008158","article-title":"RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort","volume":"6","author":"Scalzulli","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.07.003_bib0031","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ajh.26020","volume":"96","author":"Polverelli","year":"2021","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.07.003_bib0032","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2020-136622","article-title":"Haploidentical allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide in patients with myelofibrosis: a multi-institutional experience","volume":"136","author":"Kunte","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.07.003_bib0033","doi-asserted-by":"crossref","first-page":"259.e1","DOI":"10.1016\/j.jtct.2022.02.004","article-title":"Post-transplantation cyclophosphamide-based graft- versus-host disease prophylaxis with nonmyeloablative conditioning for blood or marrow transplantation for myelofibrosis","volume":"28","author":"Jain","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1053\/j.seminhematol.2026.07.003_bib0034","article-title":"Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study","author":"Jain","year":"2024","journal-title":"Blood Adv"},{"issue":"13","key":"10.1053\/j.seminhematol.2026.07.003_bib0035","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1182\/bloodadvances.2024012880","article-title":"Treatment approach and outcomes of patients with accelerated\/blast-phase myeloproliferative neoplasms in the current era","volume":"8","author":"Patel","year":"2024","journal-title":"Blood Adv"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.07.003_bib0036","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.leukres.2012.04.021","article-title":"Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase","volume":"36","author":"Cherington","year":"2012","journal-title":"Leuk Res"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.07.003_bib0037","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/bloodadvances.2021006827","article-title":"Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis","volume":"6","author":"Gagelmann","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.07.003_bib0038","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1182\/bloodadvances.2023011735","article-title":"Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN","volume":"8","author":"Davidson","year":"2024","journal-title":"Blood Adv"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.07.003_bib0039","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/ajh.26186","article-title":"Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases","volume":"96","author":"Gangat","year":"2021","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.07.003_bib0040","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1080\/10428194.2023.2173523","article-title":"Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease","volume":"64","author":"Sanber","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.07.003_bib0041","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbmt.2013.10.018","article-title":"Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research","volume":"20","author":"Gupta","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.07.003_bib0042","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"10.1053\/j.seminhematol.2026.07.003_bib0043","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bolanos-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1053\/j.seminhematol.2026.07.003_bib0044","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1182\/bloodadvances.2022007741","article-title":"HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age","volume":"6","author":"Ambinder","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.07.003_bib0045","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/j.bbmt.2019.06.034","article-title":"Myeloablative and reduced-intensity conditioned allogeneic hematopoietic stem cell transplantation in myelofibrosis: a retrospective study by the chronic malignancies working party of the European Society for Blood and Marrow Transplantation","volume":"25","author":"McLornan","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.07.003_bib0046","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41409-018-0226-1","article-title":"Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis","volume":"54","author":"Jain","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.07.003_bib0047","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.3324\/haematol.2022.281958","article-title":"Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis","volume":"108","author":"Murthy","year":"2023","journal-title":"Haematologica"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.07.003_bib0048","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","article-title":"Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients","volume":"55","author":"Spyridonidis","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.07.003_bib0049","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41409-025-02732-w","article-title":"Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the chronic malignancies working party of EBMT","volume":"61","author":"Sobieralski","year":"2026","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.07.003_bib0050","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.bbmt.2016.02.019","article-title":"Outcome after transplantation according to reduced-intensity conditioning regimen in patients undergoing transplantation for myelofibrosis","volume":"22","author":"Robin","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.07.003_bib0051","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.bbmt.2018.12.064","article-title":"Busulfan- or thiotepa-based conditioning in myelofibrosis: a phase II multicenter randomized study from the GITMO group","volume":"25","author":"Patriarca","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.07.003_bib0052","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41409-019-0653-7","article-title":"Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis","volume":"55","author":"Shouval","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.07.003_bib0053","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2014-04-572545","article-title":"MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis","volume":"124","author":"Rondelli","year":"2014","journal-title":"Blood"},{"issue":"26","key":"10.1053\/j.seminhematol.2026.07.003_bib0054","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","article-title":"Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the chronic leukemia working party of the European Group for Blood and Marrow Transplantation","volume":"114","author":"Kr\u00f6ger","year":"2009","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.07.003_bib0055","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/ajh.27741","article-title":"Poor engraftment after posttransplant cyclophosphamide graft-versus-host disease prophylaxis in patients with myelofibrosis","volume":"100","author":"Kim","year":"2025","journal-title":"Am J Hematol"},{"issue":"16","key":"10.1053\/j.seminhematol.2026.07.003_bib0056","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.07.003_bib0057","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.bbmt.2019.02.019","article-title":"Comparison of outcomes of allogeneic transplantation for primary myelofibrosis among hematopoietic stem cell source groups","volume":"25","author":"Murata","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.07.003_bib0058","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41409-021-01540-2","article-title":"Impact of donor-derived CD34\u2009+\u2009infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the chronic malignancies Working Party of the EBMT","volume":"57","author":"Czerw","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.07.003_bib0059","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bbmt.2015.10.005","article-title":"Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus kinase 1\/2 inhibitors","volume":"22","author":"Shanavas","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.07.003_bib0060","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1182\/bloodadvances.2021005035","article-title":"Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study","volume":"6","author":"Ali","year":"2022","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.07.003_bib0061","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1182\/blood-2023-178645","article-title":"Updated findings of a phase II study of ruxolitinib pre-, during- and post-hematopoietic stem cell transplantation for patients with primary or secondary myelofibrosis","volume":"142","author":"Hobbs","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.07.003_bib0062","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41408-020-0302-9","article-title":"Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis","volume":"10","author":"Jain","year":"2020","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.07.003_bib0063","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.3324\/haematol.2019.223503","article-title":"Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation","volume":"106","author":"Srour","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.07.003_bib0064","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/bjh.20003","article-title":"Serial sensitive molecular detection of JAK2 V617F is predictive of relapse after allogeneic stem cell transplantation in patients with myelofibrosis","volume":"206","author":"Nedumannil","year":"2025","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.07.003_bib0065","doi-asserted-by":"crossref","first-page":"722","DOI":"10.3324\/haematol.2012.076901","article-title":"JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse","volume":"98","author":"Lange","year":"2013","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.07.003_bib0066","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJMoa2408941","article-title":"Clearance of driver mutations after transplantation for myelofibrosis","volume":"392","author":"Gagelmann","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.07.003_bib0067","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1182\/blood-2008-11-190975","article-title":"JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation","volume":"113","author":"Kroger","year":"2009","journal-title":"Blood"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.07.003_bib0068","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1182\/blood-2009-12-260588","article-title":"Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis","volume":"116","author":"Alchalby","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.07.003_bib0069","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/bmt.2017.157","article-title":"Impact of molecular residual disease post allografting in myelofibrosis patients","volume":"52","author":"Wolschke","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.07.003_bib0070","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1038\/s41375-025-02754-9","article-title":"Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus","volume":"39","author":"Salit","year":"2025","journal-title":"Leukemia"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.07.003_bib0071","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000921","article-title":"Donor lymphocyte infusion and molecular monitoring for relapsed myelofibrosis after hematopoietic cell transplantation","volume":"7","author":"Gagelmann","year":"2023","journal-title":"Hemasphere"},{"issue":"17","key":"10.1053\/j.seminhematol.2026.07.003_bib0072","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1200\/JCO-25-02116","article-title":"Molecular-based ecosystem to improve personalized medicine in chronic myelomonocytic leukemia","volume":"44","author":"Lanino","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2026.07.003_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107345","article-title":"Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic\/myeloproliferative neoplasm with neutrophilia","volume":"131","author":"Jain","year":"2023","journal-title":"Leuk Res"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.07.003_bib0074","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1080\/10428194.2022.2057488","article-title":"Genomic landscape of myelodysplastic\/myeloproliferative neoplasm can predict response to hypomethylating agent therapy","volume":"63","author":"Karantanos","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.07.003_bib0075","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ajh.24972","article-title":"A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms","volume":"93","author":"Assi","year":"2018","journal-title":"Am J Hematol"},{"issue":"25","key":"10.1053\/j.seminhematol.2026.07.003_bib0076","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1182\/blood-2012-10-460170","article-title":"GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia","volume":"121","author":"Padron","year":"2013","journal-title":"Blood"},{"issue":"15","key":"10.1053\/j.seminhematol.2026.07.003_bib0077","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1158\/1078-0432.CCR-15-2781","article-title":"A multi-institution phase I trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML)","volume":"22","author":"Padron","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.07.003_bib0078","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1200\/JCO.22.00437","article-title":"Decitabine versus Hydroxyurea for advanced proliferative chronic myelomonocytic leukemia: results of a randomized phase III trial within the EMSCO network","volume":"41","author":"Itzykson","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.07.003_bib0079","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/bjh.18297","article-title":"Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: a combined CIBMTR\/CMWP of EBMT analysis","volume":"198","author":"Dholaria","year":"2022","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.07.003_bib0080","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjh.14619","article-title":"Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the chronic malignancies working party of the European Society for Blood and Marrow Transplantation","volume":"177","author":"Onida","year":"2017","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.07.003_bib0081","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.bbmt.2020.05.013","article-title":"Outcome of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic\/myeloproliferative neoplasms-unclassifiable: a retrospective nationwide study of the Japan Society for Hematopoietic Cell Transplantation","volume":"26","author":"Kurosawa","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"10.1053\/j.seminhematol.2026.07.003_bib0082","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood.2024028000","article-title":"Role of allo-HCT in \u2018nonclassical\u2019 MPNs and MDS\/MPNs: recommendations from the PH&G committee and the CMWP of the EBMT","volume":"145","author":"Polverelli","year":"2025","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.07.003_bib0083","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.3324\/haematol.2023.283426","article-title":"Haploidentical donor hematopoietic cell transplantation for myelodysplastic\/myeloproliferative overlap neoplasms: results from a North American collaboration","volume":"108","author":"Jain","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.07.003_bib0084","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3324\/haematol.2021.280203","article-title":"The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis","volume":"108","author":"Mei","year":"2023","journal-title":"Haematologica"},{"issue":"25","key":"10.1053\/j.seminhematol.2026.07.003_bib0085","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood.2019000622","article-title":"Mutant calreticulin in myeloproliferative neoplasms","volume":"134","author":"How","year":"2019","journal-title":"Blood"},{"issue":"22","key":"10.1053\/j.seminhematol.2026.07.003_bib0086","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1182\/blood.2024024373","article-title":"Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN","volume":"144","author":"Reis","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2026.07.003_bib0087","unstructured":"Inc MG. Mutant calreticulin\u2013specific monoclonal antibody, INCA033989, is well tolerated and achieves robust spleen, anemia, and molecular responses in patients (PTS) with myelofibrosis by Claire Harrison. 2026. Accessed July 25, 2026. https:\/\/library.ehaweb.org\/eha\/2026\/eha-2026\/4206770\/claire.harrison.mutant.calreticulinspecific.monoclonal.antibody.inca033989.is.html"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2026.07.003_bib0088","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1182\/blood-2024-204953","article-title":"Development of a first-in-class CAR-T therapy against calreticulin-mutant neoplasms and evaluation in the relevant human tissue environment","volume":"144","author":"Rampotas","year":"2024","journal-title":"Blood"},{"issue":"649","key":"10.1053\/j.seminhematol.2026.07.003_bib0089","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba4380","article-title":"Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine","volume":"14","author":"Gigoux","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.seminhematol.2026.07.003_bib0090","unstructured":"Inc MG. Results of AJX-101, a phase 1 clinical trial of the type II JAK2 inhibitor AJ1-11095, in patients with myelofibrosis who have been failed by a type I JAK2 inhibitor by Dr. John Mascarenhas. 2026. Accessed July 25, 2026. https:\/\/library.ehaweb.org\/eha\/2026\/eha-2026\/4206772\/john.mascarenhas.results.of.ajx-101.a.phase.1.clinical.trial.of.the.type.ii.html"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:58:06Z","timestamp":1792126686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196326000843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0037196326000843"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.07.003","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood or marrow transplantation and cellular therapies in myeloproliferative neoplasms: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}